Peptibase
Weight Loss

Dulaglutide

Also known as: Trulicity

FDA Approved
Share:

Popular For

Blood sugar control, weight management, diabetes

Key Facts: Dulaglutide

Category
Weight Loss
FDA Status
FDA Approved
Clinical Status
FDA Approved - Type 2 diabetes
Administration
Subcutaneous injection weekly
Typical Dose
1.5-4.5 mg weekly
Frequency
Once weekly
Evidence Level
FDA Approved
Duration
Long-term / chronic use
Also Known As
Trulicity

Mechanism of Action

Dulaglutide consists of two GLP-1 analogs linked to a modified human IgG4 Fc fragment. This structure extends half-life to about 5 days, allowing weekly dosing. Works through standard GLP-1 receptor activation.

Research Summary

AWARD program showed significant A1C reduction and weight loss. REWIND trial demonstrated cardiovascular benefits in broader diabetic population. Generally shows 3-5% weight loss in trials.

Clinical Status:FDA Approved - Type 2 diabetes
Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical Dosingⓘ

Community experience

Common Dose

1.5-4.5 mg weekly

Range

0.75-4.5 mg weekly

Frequency

Once weekly

FDA-approved as Trulicity. Titrate from 0.75 mg. Convenient once-weekly dosing.

Research Dosingⓘ

Scientific studies

FDA-approved dosing

Doses from Studies

3.0mg, 4.5mg weekly (higher doses)

FDA Approved Labeling - Prescribed dose ↗

Duration

Long-term / chronic use

Administration

Subcutaneous injection weekly

Timing & Administration

Best Time to Take

Before bed or morning (fasted)

Follow specific peptide protocol

Food Recommendation

Take on empty stomach

Why This Timing?

GH-related peptides work best on an empty stomach to maximize growth hormone release.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●Nausea
  • ●Diarrhea
  • ●Vomiting
  • ●Abdominal pain
  • ●Injection site reactions
  • ●Hypoglycemia (with insulin/sulfonylureas)
  • ●Pancreatitis
  • ●Gallbladder problems
  • ●BOXED WARNING: Thyroid C-cell tumors
  • ●FDA approved (Trulicity)

References

Related Peptides

Peptides commonly compared with Dulaglutide or used in similar applications.

Semaglutide

FDA

A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.

Weight Loss

Tirzepatide

FDA

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.

Weight Loss

Liraglutide

FDA

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.

Weight Loss

Exenatide

FDA

The first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. Available in twice-daily and weekly formulations.

Weight Loss

Retatrutide

Clinical Trials

A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.

Weight Loss

Orforglipron

Clinical Trials

An oral non-peptide GLP-1 receptor agonist. NDA under FDA review with decision expected April 10, 2026. If approved, will compete directly with oral Wegovy.

Weight Loss
How to Use DulaglutideDulaglutide AlternativesCompare with SimilarBrowse All Peptides

Looking for a trusted vendor?

Pro members get access to verified vendors with quality standards & exclusive discount codes.

View Verified Vendors
PRO

Want updates on Dulaglutide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides